Back to News
NewsRegulation

Patent Challenges for AI-Developed Medicines

AI-driven drug development faces patent hurdles in the U.S. as only human inventors can be named in applications, raising questions about future law adaptations.

Mercation Admin
August 21, 2026 1 min read
Patent Challenges for AI-Developed Medicines

Pharmaceutical firms utilizing artificial intelligence (AI) in drug creation are facing significant challenges regarding patent applications due to U.S. regulations that stipulate only human inventors can be acknowledged. This concern was noted by the MIT Technology Review.

A prominent example includes Insilico Medicine, which reported that its generative AI technology identified a promising compound for pulmonary fibrosis treatment. Remarkably, the AI itself was not credited in the patent application; instead, five human inventors, including CEO Alex Zhavoronkov, were listed.

This strategy aligns with current U.S. legal standards, which were reinforced by the 2022 DABUS case, where it was established that the term "inventor" refers solely to humans.

The DABUS case, involving an AI-created food container, clarified that U.S. law interprets "individual" specifically as a human. As a result, patent disputes increasingly center on the contributions made by humans rather than AI's role.

Ryan Abbott, a partner at Brown, Neri, Smith & Khan, cautioned that inconsistencies in how AI contributions are documented could lead to widespread challenges against patents associated with AI innovations in the future. He remarked, "If I asked Claude to cure cancer and it succeeded, I think it would be inappropriate to claim that as my achievement."

The MIT Technology Review also pointed out that the U.S. Patent and Trademark Office initially provided clarity on co-inventorship in AI contexts. However, following Donald Trump's presidency, the agency has begun to regard AI as a mere "tool like a calculator," removing the necessity for AI to be identified separately in patent filings.

Sara Corman, Chief Legal Officer at Isomorphic Labs, asserted that as AI's influence expands, existing laws will need reevaluation. Presently, companies are taking care to document human involvement in the processes of synthesis, modification, and testing of pharmaceutical compounds.

Additionally, Anthropic, an AI startup, launched Claude Science in July, aiming to assist scientists and develop treatments for serious diseases.